4Mareocei C, Bartalena L, Tanda ML, et al. Comparison of the effectiveness and tolerability of intravenous or oral glueoeortieoids associated with orbital radiotherapy in the management of severe Graves' ophthalmopathy : results of a prospective, single-blind, randomized study[J]. J Clin Endocrinol Metab, 2001,86(8):. 被引量：1
5Stiebel-Kalish H, Robenshtok E, Hasanreisoglu M, et al. Treatment modalities for Graves' ophthalmopathy: systematic review and meta analysis[ Jl. J Clin Endocrinol Metab, 2009,94 (8) :2708-2716. 被引量：1
6Bartalena L, Baldeschi L, Dickinson A, et al. Consensus statement of the European Group on Graves' orbitopathy (EUGOGO) on management of GO[ J]. Eur J Endocrinol, 2008, 158 (3) :273-285. 被引量：1
7Bartalena L, Baldeschi L, Dickinson A J, et al. Consensus statement of the European group on Graves' orbitopathy (EUGOGO) on management of Graves' orbitopathy[ J]. Thyroid, 2008,18 (3) :333-346. 被引量：1
8Zang S, Ponto KA, Kahaly GJ. Clinical review: Intravenous glucocorticoids for Graves' orbitopathy: efficacy and morbidity [ J 1. J Clin Endocrinol Metab, 2011,96 (2) :320-332. 被引量：1
9Bahn R. High-dose intravenous glucocorticoid therapy for Graves' ophthalmopathy: where are we now? [ J]. Thyroid, 2012,22 (1) :1-2. 被引量：1
10Prummel MF, Terwee CB, Gerding MN, et al. A randomized controlled trial of orbital radiotherapy versus sham irradiation in patients with mild Graves' ophthalmopathy[ J]. J Clin Endocrinol Metab, 2004,89 ( 1 ) : 15-20. 被引量：1
